Population Effectiveness, Not Efficacy, Should Decide Who Gets Vaccinated Against Human Papillomavirus via Publicly Funded Programs

This publication has 16 references indexed in Scilit:

• HPV vaccination in France: Uptake, costs and issues for the National Health Insurance
  Vaccine, 2011
• Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
  New England Journal of Medicine, 2011
• Efficacy and Safety of Prophylactic Vaccines against Cervical HPV Infection and Diseases among Women: A Systematic Review & Meta-Analysis
  BMC Infectious Diseases, 2011
• Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data
  The Lancet Infectious Diseases, 2011
• Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
  The Lancet Oncology, 2010
• Impact of vaccinating boys and men against HPV in the United States
  Vaccine, 2010
• Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States
  BMJ, 2009
• A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions
  Cancer Prevention Research, 2009
• Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine
  PharmacoEconomics, 2009
• Human papillomavirus vaccination in the United Kingdom: what about boys?
  Reproductive Health Matters, 2008